The “Accelerator Program” for selected startups and researchers provides hands-on mentoring from experts in various fields (pharmaceutical research, clinical trial design, marketing, intellectual property rights, business development, overseas expansion, fundraising, launching, and developing a startup business, data utilization, etc.).
- Junichi ImotoNissay Capital Co.,Ltd. Senior Venture Capitalist
- Tsutomu UchiyamaPatent Attorney Partner Uchiyama IP Strategies
- Kohei KatayamaDCI Partners Co.,Ltd. Director
- Kazushi KamitaniJPRO CONSULTING OFFICE
- Kaori KidoRepresentative, DeltaCeutica, LLC / Ph.D. / MBA
- Yukiharu KihoDirector, RSA (Royal Society for the Arts, Manufacturing, and Commerce) Japan Fellow Network
- Taruho KurodaLEO Science & Tech Hub, Senior Director
- Makoto ShigematsuKai Fostering Partners Inc. Representative Director
- Yoshi ShinokiClinical Development Expert
- Yoshihito DaimonMedIP Consulting G.K. President, Patent Attorney/J.D.
- Toshio NagaePharma Business Consultant (Representative) / PeptiDream (Outside Member of Board Meeting, OMBM) / Human Metabolome Technologies (OMBM) / Gifu University of Pharmacy (Visiting Professor)
- Masanobu NarutoPhronesystems (consulting) Representative,
- Ayuko NemotoSonderhoff & Einsel Law and Patent Office Partner | Attorney-at-Law
- Kenji HaradaMedical Incubator Japan K.K. Director
- Yasushi MatsuokaDirector of Clinical Development, ActualEyes Inc. / Director of Business Development, iBody inc.
- Yasuhisa MatsukawaKawasaki Institute of Industrial Promotion Lifescience Chief Coordinator
- Ichiro Mikiavatarin Inc., Director, Research and Collaboration Division
- Toshiyuki MoriTM Partners LLC CEO
- Eiichi YamaguchiA1 Partners President / Ph.D.
- Jun YamaderaEyes, JAPAN co.ltd. Chief Chaos Officer
- Kenichi YamaharaAssociate Professor, Hyogo College of Medicine. Specially Appointed Professor / Osaka University Graduate School of Medicine. CEO / CTEX Co., Ltd.
- Akihiko Watanabe, Ph.D.CBO, UnitedImmunity, Co., Ltd. / President, GlobalHumanScienceInnovation / Senior Consultant, Headland Strategy Group, Inc.
- Shinichi WatanabeK.ITO & ASSOCIATES Patents, Trademarks & Designs, Patent attorney
Junichi ImotoNissay Capital Co.,Ltd. Senior Venture Capitalist
He graduated with a master’s degree from the Division of Material Chemistry, Graduate School of Engineering, Kyoto University. He was involved in research and development of medicinal products at Fujifilm Corporation. Subsequently, he performed duties relating to patent and bibliographic information at Thomson Reuters. Since 2015, he has worked on investment activities mainly in research and development-driven venture companies at Nissay Capital Co., Ltd.
Tsutomu UchiyamaPatent Attorney Partner Uchiyama IP Strategies
Tsutomu J. Uchiyama, Ph.D. / Partner, Uchiyama IP Strategies (April 2017-) / Head of IP department (final tittle), Eisai Co., Ltd. (November 2003-March 2017) / Softbank Investment Co., Ltd. (March 2002-September 2003) / Senior director (final title), Intellectual Property Department, Takeda Pharmaceutical Co., Ltd. (June 1997- February 2002) / Researcher, Molecular Biology Lab., Daiichi Pharmaceutical Co., Ltd. (current Daiichi Sankyo Co., Ltd.) (April 1990-1997 March) / Since April 2017, as the partner of Uchiyama IP Strategies, he supports lots of start-up life science venture companies and academias. He works for matching client’s needs utilizing IP strategy planning, R & D alliances, patent application, IP due diligence, around Life science fields. Utilizing more than 20 years of experience in IP strategies at major pharmaceutical companies, etc., he provides maximum IP support for clients, thereby providing Japanese biotechnology, drug discovery, and regenerative medicine to contribute to the medical field.
Kohei KatayamaDCI Partners Co.,Ltd. Director
After graduated from the Graduate School of Pharmaceutical Sciences, Osaka University, joined Sanwa Kagaku Kenkyusho CO., LTD. He was engaged in new drug research planning, license evaluation, marketing approval application, etc. in the R & D planning department. After joining DCI Partners Co., Ltd. in 2018, he has invested in domestic and overseas drug discovery ventures as a capitalist to provide support tailored to the needs of the investees.
Kazushi KamitaniJPRO CONSULTING OFFICE
Kazushi Kamitani has been in life science industry over 20 years, experiencing broad range of jobs; product development, marketing, PR/IR, international business, business development, etc. He was also engaged with various types of products; CHC, OTC, generics, new drug, device and even dental. After being a board member of oversea subsidiary and the president of a healthcare IT venture, he started his own business, providing advisory to investing & consulting firms, and life science firms. Currently, he puts his efforts to support startups globally in the area of cross country tech transfer and fund raising, as well as business advisory.
Kaori KidoRepresentative, DeltaCeutica, LLC / Ph.D. / MBA
Joined Summit Pharmaceutical International Corporation in 2002 and engaged in due diligence of potential biotech investments and the fund management. Later, involved in drug discovery CROs business that was emerging in China, India, and Russia. In 2006, joined Shanghai ChemPartner Co., Ltd. in China a while after its establishment as a business development director, and witnessed the rapid rise of Chinese pharmaceutical industry. Through the company services, observed drug discovery and development research in Japan from the overseas company perspective. In 2016, joined Jubilant Biosys in India and engaged in the services from small molecule drug discovery to API contract manufacturing. Besides business development, report on the Japanese pharmaceutical industry as a writer for an online journal published by Elsevier, Inc., and write a column called, “World Trend Asia” published by Nikkei Biotechnology & Business since 2010.
Yukiharu KihoDirector, RSA (Royal Society for the Arts, Manufacturing, and Commerce) Japan Fellow Network
Ex- MUFG executive officer. Working experiences in New York, Tokyo, Brussels. In New York. From late 1980s to 1990s, engaged in the capital markets business including derivative transactions in New York market. In derivatives business,long career as trader, structured finace and model development. Long experience in quantitative analysis. After 2000s, engaged in overall business strategy in the American market, risk manegement and overall business development as General Manager in New York. Had more than 600 US multinational corporations as customer basis. In healthcare industries, established close relationship with Phizer, Johnson & Johnson. After returning to Japan, engaged in the business strategy with the relationships with the Blue Chips Japanese corporations. As the Deputy President of Tohgin Lease, overseeing the structured finance business , includng the aircraft finance, real estate finance. And also in charge of the investment in the healthcare venture companies.
Taruho KurodaLEO Science & Tech Hub, Senior Director
Dr. Taruho Kuroda (Taru) is the senior director of LEO Science & Tech Hub Tokyo, an external innovation arm of a global pharmaceutical company, LEO Pharma. As a portfolio worker, he provides various business consulting and mentoring services in the life science and healthcare fields, and serves as the Japan Liaison for BioLabs. He also serves as the Program Champion for Venture Cafe Tokyo’s Life Science Cluster Program as well as the impact partner for Fresco Capital. He started his career as an academic scientist and performed his research at RIKEN, Harvard Medical School, and Mie University Graduate School of Medicine. Throughout his academic career, he has been awarded prestigious fellowships from Human Frontier Science Program etc. To foster a smooth transition of scientific discoveries into real-life innovations, he pivoted his career into the pharmaceutical industry. In 2014 he joined Bayer and served as Alliance Manager / Senior Scientist at Open Innovation Center Japan. In 2019, he moved to LEO Pharma and founded an external scouting function that spearheads innovations in medical dermatology. Taru holds B.A. and Ph.D. in Pharmaceutical Sciences from Hokkaido University as well as a pharmacist license.
Makoto ShigematsuKai Fostering Partners Inc. Representative Director
He worked on a new project research and development, trial manufacture, mass production, and commercializing of glass delay line element for VTR at Asahi Glass Co., Ltd. He moved to CSKVC by making use of his relevant experience, As a venture capitalist. He engaged mainly in establishing, financing, fostering, and managing venture companies. He practiced monetizing of novel technologies, timely financing, establishing organization and management, sharing an exit strategy as a milestone, active use of intellectual property rights (open and close), and business talks and negotiations (not bargaining) hated by engineers. He has providing support for company’s growth fostered by competition and cooperation, while being employed by traditional companies for 20 years and by venture companies for 20 years with n understanding exactly the opposite of the corporate culture of both.
Yoshi ShinokiClinical Development Expert
Yoshi Shinoki has a rich experiences of clinical development in Global pharmaceuticals and he led the planning and executions of clinical development strategies and regulatory negotiations for several new compounds as Project Lead (PL). In addition, Yoshi led the planning of pricing negotiation strategies, Post Marketing Planning including PMS and PM clinical trials and Marketing strategies including sales forecast. After that, Yoshi took the role of head of regulatory consulting and led the supports of regulatory strategy planning and negotiations with PMDA and MHLW for NME, biologics, regenerative medicines (Cell therapy, gene therapy). Currently He provides some consultations for clinical development strategy planning and execution, negotiations with PMDA and MHLW and CRO management with bio-tech companies and venture companies based in Japan and outside Japan.
Yoshihito DaimonMedIP Consulting G.K. President, Patent Attorney/J.D.
After graduating from Kyushu University with a degree in genetic resources engineering, he worked at Astellas Pharma, where he was involved in intellectual property matters, and was assigned to the U.S., where he was responsible for M&A and alliances. In intellectual property litigation, he has won 12 victories and lost none, generating profits of more than 10 billion yen, by leveraging his outstanding pharmaceutical legal and IP strategies. He has also co-founded several startups and served as a director and chief legal officer. He has also served as a mentor for the Japan Patent Office’s IP Acceleration program for Startups “IPAS”. Specially Appointed Professor of OI Strategy Organization, Tohoku University.
Toshio NagaePharma Business Consultant (Representative) / PeptiDream (Outside Member of Board Meeting, OMBM) / Human Metabolome Technologies (OMBM) / Gifu University of Pharmacy (Visiting Professor)
Conducting "Commericial/Pricing Strategie for Value Optimization of R&D/Licensing Projects" as members of Individual Project Teams based as 100+ projects (In-house & Consultant based on CDA) up to 2021. Willing to share Know-how with the team members. Provided UK/US/AP Courts with Expert Reports "Quantification of Opportunity Loss ($) reflecting not successful licenses". Related 30+ Presentations at Academic & Industry meetings/symposia in EU, US & JP and Related 10+ publications during 2000 to 2021. Worked for Sanofi-Aventis as Corporate Officer, Head of Medical/Marketing & Human Resources/Upgrading Competencies. Key positions at pharma companies and consulting company. Graduated from Gifu University of Pharmacy.
Masanobu NarutoPhronesystems (consulting) Representative,
In a pharmaceutical company, he has experienced many failures and successes through his career of R&D, QA, BD/licensing and business planning/operation. Collaboration with start-up companies gave him a practical knowhow and wisdom of start-up management. After retiring from the company, he has been working in consulting business, serving as a research fellow at a think tank firm, and an adviser at several public institutions. He was involved in reviewing over 120 start-up companies at VCs, out of which around 60 were invested. He has published 38 academic papers in English (total citation, 2300) and 60 essays in Japanese.
Ayuko NemotoSonderhoff & Einsel Law and Patent Office Partner | Attorney-at-Law
She graduated from the Faculty of Law, University of Tokyo. She received her LLM from Georgetown University Law Center. A lawyer (Japan and New York State). Advisor of the International Affairs Working Group and Clinical Trial Working Group of Japan Pharmaceutical Industry Legal Affairs Association, supporter of Medical Innovation Support Office of Ministry of Health, Labour and Welfare (MEDISO) and External Corporate Auditor of a healthcare startup company. She worked for foreign-affiliated lawyer's offices (Clifford Chance LLP and K&L Gates Foreign Laws Joint Enterprise Lawyer's Office) and was temporarily seconded to legal departments of domestic and international healthcare companies, during which she was involved in public relations and corporate law. She provides advice on laws and regulations for medical devices, pharmaceutical products, regenerative medicine cosmetics and digital health. She has been involved in legal due diligence and contract negotiations for investment in and acquisition of healthcare-related venture companies and, through such experience, provides general legal support for healthcare-related venture companies (corporate, intellectual property, labor, response to M&A, contract, personal information, pharmaceutical affairs and advertising regulation, response to dispute and accident).
Kenji HaradaMedical Incubator Japan K.K. Director
He worked as a group leader of researching and developing medical drugs at a leading Japanese chemical company, he had committed pharmaceutical researches about 10 years. After moving to the head office, he was focusing on running due diligence on medical drug candidates and platform technologies coming from European and American biotech companies, from the aspect of science and intellectual properties. He started his carrier at JAFCO, a Japanese largest venture capital firm, for more than 16 years, he had been investing in Japanese and American biotechnologies and served on the board of several investees. He established rich network with most of major pharmaceutical companies and many of leading venture capitals. He is an immunologist by training, earned his PhD in pharmacology at the university of Tokyo.
Yasushi MatsuokaDirector of Clinical Development, ActualEyes Inc. / Director of Business Development, iBody inc.
Mr. Matsuoka has over 30 years’ experience of drug development and strategy planning as the expert of Biologics in Mitsubishi Tanabe Pharma. After that, he moved to Pharmaceutical Division of Fujifilm and proceeded clinical trials of anti-cancer antibody and cancer vaccine as a project manager. Furthermore, he transferred to Perseus Proteomics, subsidiary company of Fujifilm and succeeded in letting Perseus be independent from consolidated subsidiary through the completion of series C financing. At this moment, he is joining Actualeyes Inc. as Director of Clinical Development and also joining iBody Inc. as a General Manager of Business Development.
Yasuhisa MatsukawaKawasaki Institute of Industrial Promotion Lifescience Chief Coordinator
After the graduate school of pharmacy of Kyoto University, joined Mitsubishi Tanabe Pharmaceuticals and engaged in drug discovery research such as pharmacokinetics, pharmaceuticals, and DDS, as well as alliance-related work in the research planning department. Also engaged the application of Remicade, the first antibody drug in Japan. After earning PhD and MBA, joined to Takeda Pharmaceutical and engaged in the creation of new businesses, regenerative medicine, and hunting new technologies such as gene and cell therapy. In regenerative medicine, participated in T-CiRA, the joint research project between the CiRA (iPS Cell Research Institute of Kyoto University) and Takeda Pharmaceuticals. Based on these experiences and networks, trying to propose comprehensive support services from research, finding an appropriate partner to alliance management from the point of view of the practical experience of pharmaceutical company side.
Ichiro Mikiavatarin Inc., Director, Research and Collaboration Division
I established the high through put screening (HTS), involved in research of biochemistry and pharmacology, antibody drug, regenerative medicine, GLP and GCP study in the pharmaceutical company. I also managed drug screening. I managed the center of inovation (COI) program in JST from 2012 to 2016. I managed the preventive medicine using AI in RIKEN from 2016 to 2020. I recently manage healthcare project and national project "Moonshot program" in avatarin Inc. I also involved in Research Ethics Committee in Ochanomizu University. I serve on a menter of Blockbuster Tokyo 2020.
Toshiyuki MoriTM Partners LLC CEO
1992-1995: Research Fellow, the Japan Society for the Promotion of Science / 1994: Intern, Hoffmann-La Roche (NJ) / 1995-2005: The U.S. National Cancer Institute / 2005-2014: Takeda Pharmaceutical Company Iimited、2014-2018: Director & Chief Scientific Officer, a Japanese independent investment company.: Hands-on invetment to Japanese listed bioventures / 2018: CEO, TM Partners, LLC: Supporting and consulting services for venture capital, bioventure, and academia. Served as an Investment Partner of a Belgian venture capital to invest Japanese and Europe bioventures for 2 years / 2019-: Board of Director, EditForce, Co., Ltd. / 2019-: Reviewer, Cyclic Innovation for Clinical Empowerment Program (CiCLE), Japan Agency for Medical Research and Development / 2019-: Board of Director, RIBOMIC Inc. / 2020-: Deputy Director, TOYAMA Pharmaceutical Valley Development Consortium, Toyama Prefecture / 2020-: Sapporo Bio-Business Advisor, Sapporo City, Hokkaido / 2020-: Board of Director, J-Pharma Co., Ltd. / 2021-: Founding Partner, Board of Director, J-Biosciences, Co., Ltd.
Eiichi YamaguchiA1 Partners President / Ph.D.
Ph.D from Faculty of Pharmaceutical Sciences Kyushu University. Over 20 years expertise of business development at Shionogi Co., Ltd., a major pharmaceutical company as well as bioventure companies. Senior Director, Business Development & Corporate Planning Dept., Shionogi. A lot of global business experience such as the first Managing Director, Shionogi Singapore, Vice President, Shionogi Qualicaps, Inc., North Carolina, and Shionogi New York. Board of Director & President & COO, a bioventure company. The first chairman, Japan Pharma Alliance Association. The Vice Chairman, Public Private Alliance Conference associated with Infectious diseases led by Dr. Shigeru Omi. Also engaged in Director, International Committee, JPMA.
Jun YamaderaEyes, JAPAN co.ltd. Chief Chaos Officer
Jun Yamadera founded Eyes, JAPAN co. ltd. in 1995, the first IT startup from the University of Aizu, Fukushima. In the past 20 years, he has been working on various cutting edge projects such as exporting Fukushima rice via web in 1995, making world’s first virtual pottery system, making CG of historical archives of national treasure of Japanese castles, temples, traditional dances and medical motions using motion capture. He is a pioneer in Augmented Reality wearable technologies, Medical x IT and has been organizing world’s first medical security hackathon since 2012. His team won the the championship in Developers Challenge 2013 Health 2.0 in Silicon Valley. He is the Health 2.0 Fukushima Chapter Leader and a TEDxKobe 2015 Speaker. He started a project called “FUKUSHIMA Wheel” in the aftermath of the terrible disaster caused by the earthquake and nuclear accident in Fukushima, JAPAN in March 11, 2011. More than 24 years experience in Cutting Edge Technologies such as AI, Blockchain and Cyber Security. He is also advisor of Safecast and LivingAnywhere. Now he is interested in Gastrophysics, Japanese Sake, Fermentation, Bot-sourcing, Molecular Gastronomy, Computational Creativity in Future Food
Kenichi YamaharaAssociate Professor, Hyogo College of Medicine. Specially Appointed Professor / Osaka University Graduate School of Medicine. CEO / CTEX Co., Ltd.
I have conducted investigator initiated clinical trials using amnion-derived MSC and repeat PMDA consultations leads to gain knowledge of regulations for regenerative medicine. Taking advantage of this experience, Japan Biomedical Co., Ltd., which manufactures bovine serum "NeoSERA®" for regenerative medicine products, was founded in January 2017. In February 2018, CTEX Co., Ltd., a venture company from Hyogo College of Medicine, was established with the aim of developing clinical trials for cell therapy using infrastructure of college hospital. From January 2021, I also belong to Osaka University Graduate School of Medicine to expand my research field for cell therapy. Currently, I am working on the development of cell therapy originating from college hospital.
Akihiko Watanabe, Ph.D.CBO, UnitedImmunity, Co., Ltd. / President, GlobalHumanScienceInnovation / Senior Consultant, Headland Strategy Group, Inc.
Toyobo, Co., Ltd. (Apr., 1982 - Jan., 1996) , Research in various therapeutic areas, mainly immunological diseases, Senior Researcher & Product Manager of TYB-2285 / Bayer Yakuhin, Co., Ltd. (Feb., 1996 - Mar., 2002), Senior Researcher, Asthma TRA, Segment Focus Project Member, Head of Pharmacology, Technology Manager / Kyowa Kirin, Co., Ltd. (Apr., 2002 - Feb., 2015), Director, Allergic Disease TRA, Associate Director, External Relations, Manager, Local Marketing, etc. / Teva Pharmaceuticals, Co., Ltd. (Mar., 2015 -S ep., 2017), Director, Regional Marketing, Senior Manager, BD (Main task was to evaluate academia seeds in Japan and report to Global Head, BD, Teva) / NapaJen Pharma, Co., Ltd. (Oct., 2017 - Jun., 2020), Vice President, Open Innovation & Business Development / GlobalHumanScienceInnovation (Oct., 2020 - Present), President, Accelerator for start-ups to support bringing novel academia seeds to global / United Immunity (Feb., 2020 - Present), CBO, Business Development / Human Science Foundation and the Pharmaceutical Society of Japan (2010 - 2020), Having been working on the theme of discovering excellent academics and putting them into business.
Shinichi WatanabeK.ITO & ASSOCIATES Patents, Trademarks & Designs, Patent attorney
Shinichi Watanabe began his career as a patent attorney in 2003, and with the valuable experience gained at global patent law firms. His practice primarily deals with filing and prosecution of domestic and international patent applications in the pharmaceutical and biotechnology fields. Backed up by a wealth of practical experience and technical expertise, he is actively engaged in IP counselling and advises start-up pharmaceutical and biotech companies on patent filing strategies. Recently, he is interested in AI and machine learning, and provides advice in the interdisciplinary area between life science, IT and AI.